4.7 Article

Cephalosporins inhibit human metallo beta-lactamase fold DNA repair nucleases SNM1A and SNM1B/apollo

Journal

CHEMICAL COMMUNICATIONS
Volume 52, Issue 40, Pages 6727-6730

Publisher

ROYAL SOC CHEMISTRY
DOI: 10.1039/c6cc00529b

Keywords

-

Funding

  1. Medical Research Council (MRC) [MR/L007665/1]
  2. Agency for Science, Technology and Research Singapore (A<SUP>star</SUP>STAR)
  3. AbbVie [1097737]
  4. Bayer Pharma AG
  5. Boehringer Ingelheim
  6. Canada Foundation for Innovation
  7. Genome Canada
  8. Janssen
  9. Merck Co.
  10. Novartis Research Foundation
  11. Ontario Ministry of Economic Development and Innovation
  12. Pfizer
  13. Sao Paulo Research Foundation-FAPESP
  14. Takeda
  15. Wellcome Trust [092809/Z/10/Z]
  16. MRC [MR/L007665/1] Funding Source: UKRI
  17. Cancer Research UK [16466] Funding Source: researchfish
  18. Medical Research Council [MR/L007665/1] Funding Source: researchfish

Ask authors/readers for more resources

Bacterial metallo-beta-lactamases (MBLs) are involved in resistance to beta-lactam antibiotics including cephalosporins. Human SNM1A and SNM1B are MBL superfamily exonucleases that play a key role in the repair of DNA interstrand cross-links, which are induced by antitumour chemotherapeutics, and are therefore targets for cancer chemosensitization. We report that cephalosporins are competitive inhibitors of SNM1A and SNM1B exonuclease activity; both the intact b-lactam and their hydrolysed products are active. This discovery provides a lead for the development of potent and selective SNM1A and SNM1B inhibitors.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available